Cosmos Health Regains Compliance With Nasdaq Minimum Bid Price Rule
Cosmos Health Regains Compliance With Nasdaq Minimum Bid Price Rule
CHICAGO, IL / ACCESSWIRE / July 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has regained compliance with the minimum bid price requirement of $1.00 per share, as set forth in the Nasdaq Rules for continued listing on Nasdaq.
Cosmos Health Inc.("Cosmos Health"或"公司")(NASDAQ:COSM)是一家多元化、垂直整合的全球保健集團,致力於創新研發、擁有專有藥品和營養保健品牌、製造和分銷醫療產品以及經營遠程醫療平台。公司宣佈,已按照納斯達克規定,恢復了每股股票1美元的最低買盤價的合規要求,保持在納斯達克繼續上市名單中。
On July 19, 2024, Cosmos Health received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").
2024年7月19日,Cosmos Health收到了來自納斯達克股票市場("納斯達克")上市資格部的一封通知函("通知函"),通知公司已恢復遵守納斯達克上市規則5550(a)(2)號規定的最低買盤價要求("最低買盤價要求")。
To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company's shares of common stock needed to be at least $1.00 per share for a minimum of ten (10) consecutive business days. The Notification Letter confirmed that the Company achieved a closing bid price of $1.00 or greater per common share for ten (10) consecutive business days from July 5, 2024 to July 18, 2024, thereby regaining compliance with the Minimum Bid Price Requirement. Accordingly, Nasdaq has determined that this matter is now closed.
爲了符合最低買盤價要求,公司的普通股收盤買盤價格至少需要在十個(10)個連續的交易日內達到每股1美元。通知函確認,從2024年7月5日至2024年7月18日的十個連續交易日中,公司實現了每股普通股收盤買盤價爲1美元或更高,因此符合最低買盤價要求。因此,納斯達克已確定此事現已結束。
Greg Siokas, CEO of Cosmos Health, stated: "We are pleased to have regained organic compliance with the minimum bid price requirement of $1.00 per share without the need for a reverse stock split."
Cosmos Health的首席執行官Greg Siokas表示:"我們很高興在不需要進行股票拆分的情況下,恢復了每股1美元的最低買盤價的有機遵從性。"
About Cosmos Health Inc.
Cosmos Health Inc.(納斯達克:COSM)成立於2009年,總部位於內華達州,是一家全球健康醫療集團公司。公司擁有一系列專有藥品和保健品牌,包括Sky Premium Life,Mediterranation,bio-bebe和C-Sept。公司的子公司Cana Laboratories S.A.獲得歐洲GMP許可和歐洲藥品管理局認證,生產醫藥品、食品補充劑、化妝品、生物滅菌劑和醫療設備等產品,並經營歐盟內的銷售。此外,Cosmos Health還通過希臘和英國的子公司向零售藥店和批發經銷商銷售廣泛的藥品和非處方藥品,包括品牌仿製藥和OTC藥品。此外,該公司還與人工智能藥物再利用技術合作,專注於研發針對肥胖症、糖尿病和癌症等主要健康障礙的研發合作,並專注於研發新的專利營養保健品、特殊植物提取物、專有複合仿製藥和創新非處方藥品。Cosmos Health還通過收購總部位於德克薩斯州的ZipDoctor,Inc進入了遠程醫療領域。公司正在全球範圍內擴張,並在希臘的塞薩洛尼基和雅典、英國的哈洛等地設有辦事處和配送中心。 更多信息請訪問公司網站:,以及LinkedIn和X。
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , as well as LinkedIn and X.
Cosmos Health Inc.(納斯達克:COSM)於2009年在內華達州成立,是一家多元化、垂直整合的全球保健集團。公司擁有一系列專有的藥品和營養保健品牌,包括Sky Premium Life、Mediterranation、bio-bebe和C-Sept。通過其子公司Cana Laboratories S.A.的許可,該公司在歐洲聯盟範圍內製造藥品、食品補充劑、化妝品、生物殺滅劑和醫療設備,並遵守歐洲藥品管理局(EMA)的認證的歐洲良好生產規範(GMP)。Cosmos Health還通過其在希臘和英國的子公司向零售藥店和批發經銷商分銷包括品牌通用名和場外交易藥物在內的各類藥品和光合生物。此外,公司已經建立了針對肥胖症、糖尿病和癌症等主要健康障礙的研發合作關係,並獲得了人工智能藥物再利用技術增強,專注於新型專利營養保健品、特製根提取物、專有複雜通用名和創新場外交易產品的研發。Cosmos Health還通過收購位於美國德克薩斯州的ZipDoctor,Inc.進入了遠程醫療領域。擁有全球分銷平台,該公司目前正在歐洲、亞洲和北美進行擴張,並在希臘的塞薩洛尼基和雅典,以及英國的哈洛設有辦事處和分銷中心。更多信息可在, , , ,以及LinkedIn和X上獲得。
Forward-Looking Statements
前瞻性聲明
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Cosmos Health Inc.("公司")在本新聞稿中所述的事項中除了包含歷史信息外,還可能包含根據1933年修訂的《證券法》第27A條和1934年修訂的《證券交易法》第21E條的前瞻性陳述。前瞻性聲明涉及未知的風險和不確定性,可能因以下原因之一而對討論的事項產生個別或實質性影響,這在公司的控制範圍之外,包括但不限於公司籌集足夠融資實施其業務計劃的能力,新冠病毒大流行和烏克蘭戰爭對公司業務、運營和經濟的影響以及公司成功開發和商業化自有產品和技術的能力。讀者應該注意不要過度依賴這些前瞻性聲明,因爲實際結果可能與本新聞稿中所述的前瞻性聲明不同。讀者應該注意閱讀證券交易委員會的風險因素,該委員會在其網站上(www.sec.gov)提供了這些信息。本公司不承擔更新或修訂任何前瞻性陳述的義務。
Investor Relations Contact:
投資者關係聯繫人:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
資訊來源:Cosmos Health Inc.
譯文內容由第三人軟體翻譯。